Nikolai Strusberg, MD, discussed how proton therapy and thyroid dose affect clinical hypothyroidism risk after supraclavicular breast radiation.
|Videos|December 13, 2018
Managing Patients With Moderate Penetrance Genes
Author(s)Susan M. Domchek, MD
Dr. Susan Domchek discusses the increased understanding of moderate penetrance genes and the importance of managing patients with these genes on a case-by-case basis.
Advertisement
Dr. Susan Domchek discusses the increased understanding of moderate penetrance genes and the importance of managing patients with these genes on a case-by-case basis.
Advertisement
Related to this article
Data from the phase 3 HER2CLIMB-05 study support the FDA approval of tucatinib-based maintenance treatment in HER2-positive metastatic breast cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
VS-7375 Yields Responses in KRAS G12D–Mutated Solid Tumors
2
Reading a Changed Eye Examination and Impact on Therapy
3
Personalized Cancer Vaccine Combo Is Feasible in Platinum-Sensitive Ovarian Cancer
4
Proton Therapy Tied to Less Hypothyroidism After Supraclavicular Breast RT
5